Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice

<table class="table-group" width="800px"><tr class="fig-image" id="a"><td><img alt="806391.fig.002a" src="https://static.hindawi.com/articles/bmri/volume-2014/806391/figures/806391.fig.002a.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(a) </b>7 months (2–34)</td></tr></table></td></tr><tr class="fig-image" id="b"><td><img alt="806391.fig.002b" src="https://static.hindawi.com/articles/bmri/volume-2014/806391/figures/806391.fig.002b.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(b) </b>9 months (4–35+)</td></tr></table></td></tr></table>

<table>Kaplan-Meier survival estimate. Patients treated with sorafenib. (a) Progression-free survival. (b) Overall survival.</table>

BioMed Research International

fig2

Figure 2

Figure 2: Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice 